Pharma’s Take on Drug Pricing Data Transparency in South Korea

Korea’s drug pricing policies are complex and lack transparency, according to Eli Lilly Korea’s General Manager Christopher J. Stokes. Stokes notes that he has spent considerable time talking with other pharma leaders, who generally agree with his take on the complicated nature of the South Korean Market.

According to Lee Han-soo, “Stokes noted that the Korean regulator seemed to make more data-driven, positive, and logical decisions, compared to some other countries. However, meaningful decisions could be made ‘when everyone can access data so that the decisions can be understood even by third parties,’ he said. From this point of view, Stokes hoped that the Korean government could allow data accessibility for pharmaceutical companies at a level similar to the government.

To read more, click here.

(Source: Korean Biomedical Review, March 13^th, 2023)